Ali Someili

Dr. Ali Someili


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAli Someili
Ali Someili
MMMostafa Mohrag
Mostafa Mohrag
MAMohammed Abdulrasak
Mohammed Abdulrasak
Background/Objectives: Catha edulis, also known as Khat, is a stimulant with hepatotoxic properties. Studies reporting laboratory patterns are scarce. The aim was to assess the patterns associated with hepatic dysfunction due to Khat usage. Methods: Patients with liver injury and self-reported Khat consumption presenting to the gastroenterology department at the King Fahad Central Hospital in Jazan between January 2017–May 2024 were retrospectively included in the study. Patients with any signs of cirrhosis or viral hepatitis were excluded to have a more homogenous inclusion. Normal distribution was not assumed; data were presented as the median (IQR or %). Results: Sixty-three patients (of which 62 (98.4%) were male) aged 35 (29–41) years were included in the study. An IgG > 20 g/L was present in 41 (61.5%) patients, and the majority (n = 48, 76.2%) had a hepatocellular injury pattern based on an R-factor > 5. Over half of the patients had at least one positive autoantibody(ANA 47.6%; SMA 55.6% and AMA 4.8%), while 57 (90.5%) patients received immunosuppressive therapy. Conclusions: Khat-induced liver injury seems to be predominantly AIH-like in nature, given the IgG elevation, hepatocellular injury pattern, and relatively high rate of autoantibody positivity.

1 January 2025 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
ASAli Someili
Ali Someili
SMSarah Jaber Mobarki
Sarah Jaber Mobarki
RMRazan Hamoud Moafa
Razan Hamoud Moafa
LALeena Nageeb Alsury
Leena Nageeb Alsury
RSRoaa Hassan Shadad
Roaa Hassan Shadad
MAMohammed Abdulrasak
Mohammed Abdulrasak
Background: Upper gastrointestinal bleeding (UGIB) is a common and potentially fatal medical emergency. This study aimed to investigate the frequency, causes, outcomes, and efficacy of endoscopy in the treatment of UGIB at King Fahad Central Hospital in Jazan, Saudi Arabia. Methods: Between January 2017 and December 2023, a retrospective study was performed including all hospitalized patients with UGIB. This research investigated sociodemographic characteristics, clinical history, endoscopic findings, treatment options, and results using statistical analysis, which included both descriptive and inferential approaches. Results: The study included 483 patients (of which 74.1% men), with a mean age of 53.9 ± 19.5 years. Hematemesis was observed in 67.5% of the patients, whereas melena occurred in 49.7% of the cases. Two-hundred sixty-two (54.2%) patients underwent endoscopy within the first 24 h from presentation. The most frequent endoscopic findings were esophageal varices (52.2%) and duodenal ulcers (21.7%). Bandings accounted for 48.0% of all endoscopic procedures, whereas 36.9% of the patients received epinephrine injections along with endoclips. Medical therapy mostly consisted of a mix of proton pump inhibitors (PPIs) and octreotide. A significant minority (43.5%) of the patients stayed in the hospital for 1 - 3 days, while 59.6% did not need blood transfusions. During the first 3 days, 7% of patients experienced rebleeding, with a 6% mortality rate. Using multivariate regression analysis, rebleeding was strongly associated with initial presentation with shock (P < 0.001), renal disease (P = 0.01), and increased transfusion requirement (P = 0.001). Mortality was strongly associated with steroid usage (P = 0.007), increasing transfusion requirements (P < 0.0001), and rebleeding (P = 0.002). Conclusions: Timely endoscopy and proper treatment dramatically improved UGIB results. Identifying those who are at high risk and acting swiftly is a critical step in reducing the likelihood of recurrent bleeding and fatality.

1 February 2025 in Gastroenterology Research
Verified
Journal Article
Open access
PDF file
ASAli Someili
Ali Someili
AMAmani A. Mutaen
Amani A. Mutaen
AAAbdullah M. Alqahtani
Abdullah M. Alqahtani
RMRaghad A. Mobaraki
Raghad A. Mobaraki
YMYara A. Mutaen
Yara A. Mutaen
MAMohammed Abdulrasak
Mohammed Abdulrasak
Background: Irritable bowel syndrome (IBS) is the major form of functional bowel disorders, where the diagnosis is based on set criteria and characterized by abdominal pain and changes in bowel habits. Epidemiological data, alongside self-reported outcomes, are of interest with regard to IBS, as these factors may need to be addressed to optimize underlying IBS. This study aims to examine the effect of IBS on certain aspects of life, including sleep quality alongside some epidemiological aspects with regards to the presence of IBS in the Jazan region of Saudi Arabia. Methods: Individuals were invited to participate in the study by replying to a validated questionnaire, whereby respondents self-identified as having IBS or not. Non-parametric comparisons using Fisher’s exact test, between those with self-reported IBS versus those without IBS, were performed, with P < 0.05 considered significant. Results: Of 728 respondents, 244 (33.5%) had self-reported IBS, and 484 (66.5%) did not. Respondents with IBS were more likely female (P < 0.001), younger age (P = 0.002), city-dwelling (P = 0.028), divorced (P = 0.028) and smokers (P = 0.003). Overall, education level did not differ amongst the groups (P = 0.093). A minority (13.5%) of those with self-reported IBS were diagnosed by a gastroenterology specialist. Abdominal pain, distension, constipation and diarrhea were all more prevalent (P < 0.001) in the IBS group compared to the non-IBS group. The IBS group had poorer sleep quality compared to the non-IBS group (P = 0.006), although no difference in medications for sleep was present between the two groups (P = 0.271). Conclusions: Self-reported IBS was highly prevalent in our region, with risk factors for its presence being similar to those reported in previous studies. Sleep deprivation was highly prevalent in IBS patients, albeit not leading to increased prescription of relevant therapies for aid of sleep in these patients. However, marital separation and city-dwelling seemed to confer a higher self-reported IBS status. These issues should be investigated using more robust, Rome IV criteria-centered questionnaires in the future.

20 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MAMohammed Abdulrasak
Mohammed Abdulrasak
ASAli Someili
Ali Someili
MMMostafa Mohrag
Mostafa Mohrag
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used in patients with type 2 diabetes, chronic kidney disease, and heart failure. However, their safety and efficacy in patients with congenital or surgically altered urogenital anatomy remains underexplored. Methods: We conducted a narrative review of current evidence regarding the use of SGLT2i in patients with urinary tract malformations, urinary diversions, and functional voiding disorders. Key risks, clinical considerations, and management strategies were synthesized from the existing literature and case reports. Results: Patients with benign prostatic hyperplasia, vesicoureteral reflux, neurogenic bladder, nephrostomies, and ileal conduits may face increased risks of urinary tract infections, fungal colonization, and therapy-related complications due to persistent glycosuria and altered urinary flow. Nevertheless, these patients may still benefit from SGLT2i’s systemic renal and cardiovascular effects. Individualized risk assessment, close monitoring, and multidisciplinary management are essential. Conclusions: Patients with urological abnormalities represent a high-risk but potentially high-reward population for SGLT2i therapy. A cautious, tailored approach is necessary, and future dedicated research is urgently needed to better guide clinical practice.

20 August 2025 in Annals of African Medicine
Verified
Journal Article
Open access
ASAli Someili
Ali Someili
ASAbdulrahman Mohammed Safhi
Abdulrahman Mohammed Safhi
AAAli Ibrahim Alharbi
Ali Ibrahim Alharbi
SAShatha Khalid Alharbi
Shatha Khalid Alharbi
NFNaseem Abdo Fqiry
Naseem Abdo Fqiry
MAMohammed Abdulrasak
Mohammed Abdulrasak
Background: Peptic ulcer disease (PUD) is characterized by an ulcer in the gastric or duodenal mucosa, approximately 3–5 mm deep. This global health concern significantly impacts health and quality of life, necessitating increased public awareness for the prevention and control of its risk factors. Materials and Methods: The study employed a cross-sectional online questionnaire targeting 400 adults from Jazan, Saudi Arabia. Adapted from existing literature, the questionnaire was disseminated online. Data were organized using Excel and analyzed via SPSS Version 27, utilizing the Chi-square test to evaluate demographic factors’ influence on awareness of PUD. Results: Among participants, 310 (77.5%) correctly identified Helicobacter pylori ( H. pylori) infection as a common cause, and 205 (51.2%) acknowledged smoking as a risk factor. Awareness of H. pylori and nonsteroidal anti-inflammatory drugs as major contributors to PUD was noted in 181 (45.3%) participants. Furthermore, 221 (55.3%) understood that antibiotics and acid suppression therapy are viable treatment options. Overall, 249 (62.25%) participants demonstrated a good level of awareness. Significant associations were found between awareness levels and demographic factors, including age, education level, and occupation, with P < 0.05 (0.006*, 0.002*, and 0.001*, respectively). Conclusion: The study highlights a considerable level of awareness about PUD among adults in Jazan, emphasizing the importance of targeted educational initiatives to further enhance understanding and prevention efforts.

22 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMostafa Mohrag
Mostafa Mohrag
ASAli Someili
Ali Someili
EEErwa Elmakki
Erwa Elmakki
MAMohammed Abdulrasak
Mohammed Abdulrasak
Direct-acting antiviral (DAA) therapy has dramatically transformed the management of hepatitis C virus (HCV) infection in chronic kidney disease (CKD). Severe renal impairment and dialysis dependence are no longer considered major barriers to virologic cure. The main difficulties have shifted toward efficient diagnosis, choosing the regimen in the presence of cirrhosis and drug interactions, coordinating treatment with kidney transplantation, managing HCV-associated immune-complex kidney disease, and providing treatment in dialysis and resource-limited settings. This narrative review aims to discuss these issues in a decision-oriented manner, using verified guidelines, systematic reviews, important clinical trials, transplant cohorts, and studies of cryoglobulinemic disease, while explicitly comparing the strength and consistency of the underlying evidence and highlighting areas of genuine clinical uncertainty. Present evidence supports using the recommended DAA regimens without renal dose adjustment, while ribavirin needs dose modification when kidney function is reduced and can result in hemolytic anemia. Kidneys from HCV-viremic donors can be transplanted to recipients without HCV infection when proper informed consent, rapid access to DAA treatment, and organized post-transplant monitoring are available, although the minimum effective duration of peri-transplant antiviral prophylaxis remains unresolved. Antiviral therapy is the first-line treatment for HCV-associated glomerular disease, while rituximab-based immunosuppression is largely reserved for severe, rapidly progressive, or persistent cryoglobulinemic vasculitis. Future progress will depend less on proving antiviral efficacy and more on closing the gaps between screening, confirmatory testing, starting treatment, transplantation pathways, and long-term follow-up, gaps that stem from inequities in diagnostic infrastructure, drug reimbursement, and healthcare-system organization as much as from any remaining biomedical uncertainty.